Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46,284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.
Wu J, Jiang Z, Liu Z, Yang B, Yang H, Tang J, Wang K, Liu Y, Wang H, Fu P, Zhang S, Liu Q, Wang S, Huang J, Wang C, Wang S, Wang Y, Zhen L, Zhu X, Wu F, Lin X, Zou J. Wu J, et al. Among authors: liu z, liu y, liu q. BMC Med. 2022 Dec 27;20(1):498. doi: 10.1186/s12916-022-02708-3. BMC Med. 2022. PMID: 36575513 Free PMC article. Clinical Trial.
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.
Ma F, Yan M, Li W, Ouyang Q, Tong Z, Teng Y, Wang Y, Wang S, Geng C, Luo T, Zhong J, Zhang Q, Liu Q, Zeng X, Sun T, Mo Q, Liu H, Cheng Y, Cheng J, Wang X, Nie J, Yang J, Wu X, Wang X, Li H, Ye C, Dong F, Wu S, Zhu X, Xu B; PHILA Investigators. Ma F, et al. Among authors: liu h, liu q. BMJ. 2023 Oct 31;383:e076065. doi: 10.1136/bmj-2023-076065. BMJ. 2023. PMID: 37907210 Free PMC article. Clinical Trial.
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial.
Jiang Z, Ouyang Q, Sun T, Zhang Q, Teng Y, Cui J, Wang H, Yin Y, Wang X, Zhou X, Wang Y, Sun G, Wang J, Zhang L, Yang J, Qian J, Yan M, Liu X, Yi T, Cheng Y, Li M, Zang A, Wang S, Wang C, Wu X, Cheng J, Li H, Lin Y, Geng C, Gu K, Xie C, Xiong H, Wu X, Yang J, Li Q, Chen Y, Li F, Zhang A, Zhang Y, Wu Y, Nie J, Liu Q, Wang K, Mo X, Chen L, Pan Y, Fu P, Zhang H, Pang D, Sheng Y, Han Y, Wang H, Cang S, Luo X, Yu W, Deng R, Yang C, Keegan P. Jiang Z, et al. Among authors: liu x, liu q. Nat Med. 2024 Jan;30(1):249-256. doi: 10.1038/s41591-023-02677-x. Epub 2024 Jan 8. Nat Med. 2024. PMID: 38191615 Clinical Trial.
Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase II single-arm study.
Yang Y, Jin L, Li Y, Rao N, Gong C, Li S, Wu J, Zhao J, Ding L, Gan F, Zhang J, Feng R, Liu Z, Liu Q. Yang Y, et al. Among authors: liu z, liu q. Chin J Cancer Res. 2024 Feb 29;36(1):55-65. doi: 10.21147/j.issn.1000-9604.2024.01.06. Chin J Cancer Res. 2024. PMID: 38455369 Free PMC article.
CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis.
Wang T, Chen J, Yang J, Fu M, Hua W, Jia W, Liu Y, Wang B, Yan M, Zhou J, Hao C, Chen J, Ou D, Jiang T, Mao Y, Jiang Z; CSCO expert panel of breast cancer*; CSCO expert panel of breast cancer. Wang T, et al. Transl Breast Cancer Res. 2022 Jul 30;3:22. doi: 10.21037/tbcr-22-30. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751521 Free PMC article. Review.
Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022.
Jiang Z, Li J, Chen J, Liu Y, Wang K, Nie J, Wang X, Hao C, Yin Y, Wang S, Yan M, Wang T, Yan Y, Chen X, Song E; CSCO BC guideline working group. Jiang Z, et al. Transl Breast Cancer Res. 2022 Apr 30;3:13. doi: 10.21037/tbcr-22-21. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751537 Free PMC article. Review.
Expert consensus on the clinical application of immunotherapy in breast cancer: 2024.
Wang K, Yang J, Wang B, Liu Q, Wang X, Yin Y, Wang H, Wang S, Hao C, Hao X, Liu Y, Jiang Z; Chinese Society of Clinical Oncology Breast Cancer Committee*; Chinese Society of Clinical Oncology Breast Cancer Committee. Wang K, et al. Among authors: liu y, liu q. Transl Breast Cancer Res. 2024 Apr 29;5:9. doi: 10.21037/tbcr-24-15. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 38751677 Free PMC article. Review.
BOLERO-5: a phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER + /HER2- advanced breast cancer.
Shao ZM, Cai L, Wang S, Hu X, Shen K, Wang H, Li H, Feng J, Liu Q, Cheng J, Wu X, Wang X, Li H, Luo T, Liu J, Amin K, Slimane K, Qiao Y, Liu Y, Tong Z. Shao ZM, et al. Among authors: liu j, liu y, liu q. Discov Oncol. 2024 Jun 21;15(1):237. doi: 10.1007/s12672-024-01027-8. Discov Oncol. 2024. PMID: 38904918 Free PMC article.
Initial ribociclib plus endocrine therapy for HR+/HER2- advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study.
Shao Z, Tong Z, Liu Q, Li W, Cai L, Shen K, Li H, Wang C, Yang J, Song Z, Wang S, Luo T, Zhao W, Wang H, Pan Y, Nie J, Zeng X, Bai Y, Chiang W, Guarnaccia V, Bi Y, Xu B. Shao Z, et al. Among authors: liu q. Cancer Med. 2024 Aug;13(15):e7408. doi: 10.1002/cam4.7408. Cancer Med. 2024. PMID: 39136200 Free PMC article. Clinical Trial.
Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024.
Li J, Hao C, Wang K, Zhang J, Chen J, Liu Y, Nie J, Yan M, Liu Q, Geng C, Wang X, Wang H, Wang S, Wu J, Yin Y, Song E, Jiang Z. Li J, et al. Among authors: liu y, liu q. Transl Breast Cancer Res. 2024 Jul 25;5:18. doi: 10.21037/tbcr-24-31. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39184927 Free PMC article. Review.
46,284 results
You have reached the last available page of results. Please see the User Guide for more information.